JPH05500055A - ５―アミノ―１，２，３，４―テトラヒドロアクリジンの誘導体および医薬としての使用 - Google Patents

５―アミノ―１，２，３，４―テトラヒドロアクリジンの誘導体および医薬としての使用

Info

Publication number: JPH05500055A
Authority: JP; Japan
Prior art keywords: tha; group; compound; salt; rats
Prior art date: 1989-08-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2512400A

Other languages

English (en)

Japanese (ja)

Inventor

ニュイエン　ダット　スオング

ラパン　ジャン　ロベール

ピュエイオ　ジャック

Original Assignee

シンテーズ　エ　ルシェルシェ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-25

Filing date

1990-08-24

Publication date

1993-01-14

1990-08-24 Application filed by シンテーズ　エ　ルシェルシェ filed Critical シンテーズ　エ　ルシェルシェ

1993-01-14 Publication of JPH05500055A publication Critical patent/JPH05500055A/ja

Status Pending legal-status Critical Current

Links

239000003814 drug Substances 0.000 title claims description 8
229940079593 drug Drugs 0.000 title claims description 5
MOWGHIVIVXUXBY-UHFFFAOYSA-N 5,6,7,8-tetrahydroacridin-4-amine Chemical class C1CCCC2=C1C=C1C=CC=C(N)C1=N2 MOWGHIVIVXUXBY-UHFFFAOYSA-N 0.000 title claims description 4
150000001875 compounds Chemical class 0.000 claims description 46
238000011282 treatment Methods 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 12
208000030507 AIDS Diseases 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
-1 isatinyl group Chemical group 0.000 claims description 9
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 8
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 8
206010016654 Fibrosis Diseases 0.000 claims description 7
230000007882 cirrhosis Effects 0.000 claims description 7
208000019425 cirrhosis of liver Diseases 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
230000003412 degenerative effect Effects 0.000 claims description 6
SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical class OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 4
239000002126 C01EB10 - Adenosine Substances 0.000 claims description 4
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 4
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 4
206010012289 Dementia Diseases 0.000 claims description 4
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 4
229930010555 Inosine Natural products 0.000 claims description 4
229960005305 adenosine Drugs 0.000 claims description 4
125000003147 glycosyl group Chemical group 0.000 claims description 4
229940029575 guanosine Drugs 0.000 claims description 4
229960003786 inosine Drugs 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
125000004032 5'-inosinyl group Chemical group 0.000 claims description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 2
159000000021 acetate salts Chemical class 0.000 claims description 2
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
239000002777 nucleoside Substances 0.000 claims description 2
125000003835 nucleoside group Chemical group 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
229940127557 pharmaceutical product Drugs 0.000 claims description 2
208000021642 Muscular disease Diseases 0.000 claims 3
201000009623 Myopathy Diseases 0.000 claims 3
206010039966 Senile dementia Diseases 0.000 claims 3
125000002124 5'-adenosyl group Chemical group N1=CN=C2N(C=NC2=C1N)[C@H]1[C@H](O)[C@H](O)[C@H](O1)C* 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 44
241000700159 Rattus Species 0.000 description 32
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 32
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
235000010323 ascorbic acid Nutrition 0.000 description 22
239000011668 ascorbic acid Substances 0.000 description 22
229940072107 ascorbate Drugs 0.000 description 21
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
235000019441 ethanol Nutrition 0.000 description 16
239000000243 solution Substances 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
239000000047 product Substances 0.000 description 14
230000000694 effects Effects 0.000 description 11
238000002329 infrared spectrum Methods 0.000 description 10
238000002844 melting Methods 0.000 description 10
230000008018 melting Effects 0.000 description 10
239000000843 powder Substances 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
229910052799 carbon Inorganic materials 0.000 description 9
239000001257 hydrogen Substances 0.000 description 9
229910052739 hydrogen Inorganic materials 0.000 description 9
229910052757 nitrogen Inorganic materials 0.000 description 9
238000002211 ultraviolet spectrum Methods 0.000 description 9
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
150000001298 alcohols Chemical class 0.000 description 6
238000012512 characterization method Methods 0.000 description 6
150000002334 glycols Chemical class 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000013078 crystal Substances 0.000 description 5
150000002431 hydrogen Chemical class 0.000 description 5
239000004570 mortar (masonry) Substances 0.000 description 5
230000011514 reflex Effects 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
208000000112 Myalgia Diseases 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
230000007059 acute toxicity Effects 0.000 description 3
231100000403 acute toxicity Toxicity 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
229960001231 choline Drugs 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
108010078430 glutamine phenylacetyltransferase Proteins 0.000 description 2
231100000304 hepatotoxicity Toxicity 0.000 description 2
210000003127 knee Anatomy 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
230000007056 liver toxicity Effects 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
231100001092 no hepatotoxicity Toxicity 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000000376 reactant Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
HABAPWZXRLIZDL-UHFFFAOYSA-N 2-chloro-2-phenoxyacetic acid Chemical class OC(=O)C(Cl)OC1=CC=CC=C1 HABAPWZXRLIZDL-UHFFFAOYSA-N 0.000 description 1
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
MBVCESWADCIXJN-UHFFFAOYSA-N 5-Bromoisatin Chemical compound BrC1=CC=C2NC(=O)C(=O)C2=C1 MBVCESWADCIXJN-UHFFFAOYSA-N 0.000 description 1
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
239000011547 Bouin solution Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
208000004930 Fatty Liver Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010018852 Haematoma Diseases 0.000 description 1
XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
206010049816 Muscle tightness Diseases 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
206010039424 Salivary hypersecretion Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
230000002303 anti-venom Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000003763 carbonization Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
230000006949 cholinergic function Effects 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
230000002566 clonic effect Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
231100000895 deafness Toxicity 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000006266 hibernation Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000463 material Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229910052758 niobium Inorganic materials 0.000 description 1
239000010955 niobium Substances 0.000 description 1
GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
FKGFBYXUGQXYKX-UHFFFAOYSA-N phenyl ethaneperoxoate Chemical class CC(=O)OOC1=CC=CC=C1 FKGFBYXUGQXYKX-UHFFFAOYSA-N 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
239000003169 respiratory stimulant agent Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
208000026451 salivation Diseases 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000007863 steatosis Effects 0.000 description 1
231100000240 steatosis hepatitis Toxicity 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000035900 sweating Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP2512400A 1989-08-25 1990-08-24 ５―アミノ―１，２，３，４―テトラヒドロアクリジンの誘導体および医薬としての使用 Pending JPH05500055A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8911283A FR2651230B1 (fr)	1989-08-25	1989-08-25	Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et applications comme medicaments.
FR89/11283		1989-08-25

Publications (1)

Publication Number	Publication Date
JPH05500055A true JPH05500055A (ja)	1993-01-14

Family

ID=9384932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2512400A Pending JPH05500055A (ja)	1989-08-25	1990-08-24	５―アミノ―１，２，３，４―テトラヒドロアクリジンの誘導体および医薬としての使用

Country Status (5)

Country	Link
EP (1)	EP0487623A1 (de)
JP (1)	JPH05500055A (de)
CA (1)	CA2064999A1 (de)
FR (1)	FR2651230B1 (de)
WO (1)	WO1991002725A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006514922A (ja) *	2002-10-09	2006-05-18	ニューロファルマ・ソシエダード・アノニマ	アルツハイマー病を治療するための、二重結合部位アセチルコリンエステラーゼ阻害剤
US7910739B2 (en)	2003-07-09	2011-03-22	Noscira, S.A.	Acetylcholinesterase dual inhibitors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9103752D0 (sv) *	1991-12-18	1991-12-18	Astra Ab	New compounds
RU2036198C1 (ru) *	1993-04-01	1995-05-27	Товарищество с ограниченной ответственностью "Полисан"	N-МЕТИЛ-N-( α,D -ГЛЮКОПИРАНОЗИЛ) АММОНИЯ-2-(АКРИДОН-9-ОН-10-ИЛ)АЦЕТАТ(ЦИКЛОФЕРОН), ОБЛАДАЮЩИЙ ИНТЕРФЕРОНОГЕННОЙ, ПРОТИВОВИРУСНОЙ, В ТОМ ЧИСЛЕ АНТИВИЧ, АНТИПАРАЗИТАРНОЙ, АНТИПРОМОТОРНОЙ И РАДИОПРОТЕКТИВНОЙ АКТИВНОСТЬЮ
PL207853B1 (pl) *	2000-04-04	2011-02-28	Fundacja Rozwoju Diagnostyki I Terapii	Nowe (1-adamantyloamino)pirydyny, sposób ich wytwarzania i zastosowanie medyczne
DE10132726A1 (de)	2001-07-05	2003-02-27	Gruenenthal Gmbh	Verwendung von substituierten gamma-Lactonverbindungen als Arzneimittel
WO2012154879A2 (en) *	2011-05-09	2012-11-15	Van Andel Research Institute	Autophagy inhibitors
CN105330646B (zh) *	2015-12-04	2019-05-24	上海勋和医药科技有限公司	一种抗肿瘤药马来酸来那替尼的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR3860M (fr) *	1962-12-21	1966-01-24	Madan Ag	Acides halogénophénoxyacétiques et leurs sels.
US4816456A (en) *	1986-10-01	1989-03-28	Summers William K	Administration of monoamine acridines in cholinergic neuronal deficit states
US4985430A (en) *	1987-12-03	1991-01-15	Mitsubishi Kasei Corporation	9-acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient

1989
- 1989-08-25 FR FR8911283A patent/FR2651230B1/fr not_active Expired - Fee Related
1990
- 1990-08-24 JP JP2512400A patent/JPH05500055A/ja active Pending
- 1990-08-24 WO PCT/FR1990/000630 patent/WO1991002725A1/fr not_active Ceased
- 1990-08-24 EP EP90913286A patent/EP0487623A1/de not_active Withdrawn
- 1990-08-24 CA CA002064999A patent/CA2064999A1/fr not_active Abandoned

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006514922A (ja) *	2002-10-09	2006-05-18	ニューロファルマ・ソシエダード・アノニマ	アルツハイマー病を治療するための、二重結合部位アセチルコリンエステラーゼ阻害剤
US7910739B2 (en)	2003-07-09	2011-03-22	Noscira, S.A.	Acetylcholinesterase dual inhibitors

Also Published As

Publication number	Publication date
FR2651230A1 (fr)	1991-03-01
EP0487623A1 (de)	1992-06-03
WO1991002725A1 (fr)	1991-06-07
FR2651230B1 (fr)	1992-03-13
CA2064999A1 (fr)	1991-02-26

Publication	Publication Date	Title
DE3784905T2 (de)	1993-08-05	Gamma-l-glutamyl-l-cysteinethylester und arzneimittel, die dieses als aktives mittel enthalten.
US20150353467A1 (en)	2015-12-10	3,4-diaminopyridine tartrate and phosphate, pharmaceutical compositions and uses thereof
GB2184653A (en)	1987-07-01	Dementia improving and therapeutic agents
JPH05500055A (ja)	1993-01-14	５―アミノ―１，２，３，４―テトラヒドロアクリジンの誘導体および医薬としての使用
HU207321B (en)	1993-03-29	Process for producing n-/amino-carbonyl/-carbamates related to the fizostigmine and pharmaceutical compositions containing them
DE60035988T2 (de)	2008-05-08	Eisenchelatoren und arzneimittel enthaltend eisenchelatoren zur behandlung von neurodegenerativen erkrankungen
JPS61171495A (ja)	1986-08-02	白金錯体類及びその製造方法
US11434198B2 (en)	2022-09-06	Compounds and methods for the treatment of neurodegenerative diseases
JPH03503162A (ja)	1991-07-18	化学療法における毒性特性の改良
US4822817A (en)	1989-04-18	Remedy for bone disease
US5621003A (en)	1997-04-15	Maillard reaction inhibitor
EP1970372A2 (de)	2008-09-17	Salze von 9-oxoacridin-10-essigsäure mit 1-alkylamino-1-desoxypolyolen
DE69001004T2 (de)	1993-07-15	Zusammensetzung gegen leberkrankheiten.
DE69209115T2 (de)	1996-08-01	Sauerstoffradikalfänger
US10307424B2 (en)	2019-06-04	Drug with hepatoprotective activity
JPH11505240A (ja)	1999-05-18	減量用薬剤
JPH02503797A (ja)	1990-11-08	脂質の減少、酸素に対するヘモグロビンの親和力の修正ならびに血小板凝集の抑制を行うための化合物、組成物および方法
CA1337972C (en)	1996-01-23	Agent for treating hyperuricemia
JPH04208223A (ja)	1992-07-29	肝臓疾患治療剤
KR19980703718A (ko)	1998-12-05	다발성 경화증의 치료에 유용한 생물학적 활성 우레이도 유도체
JPH072867A (ja)	1995-01-06	ビオチンアミド誘導体の製造方法及び、それらを含有する糖尿病及び糖尿病合併症の治療剤
RU2045268C1 (ru)	1995-10-10	Противогистаминное и антиаллергическое средство и способ приготовления глутамината хинуклидил-3-дифенилкарбинола в виде раствора для инъекций
CN113461528B (zh)	2024-06-25	一种苯氧酸类衍生物及其应用
CA2699403A1 (en)	2009-03-19	Pharmaceutical composition with anti-diabetic action
SU1614761A3 (ru)	1990-12-15	Способ получени диэтилдитиокарбамата холина

JPH05500055A - ５―アミノ―１，２，３，４―テトラヒドロアクリジンの誘導体および医薬としての使用 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=9384932

Family Applications (1)

Country Status (5)

Cited By (2)

Families Citing this family (6)

Family Cites Families (3)

Cited By (2)

Also Published As

Similar Documents